ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2009;88:1714-1722. doi:10.1016/j.athoracsur.2009.05.079
© 2009 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Yue Wang
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Herrmann, J. L.
Right arrow Articles by Meldrum, D. R.
PubMed
Right arrow Articles by Herrmann, J. L.
Right arrow Articles by Meldrum, D. R.
Related Collections
Right arrow Molecular biology

Review

Cell-Based Therapy for Ischemic Heart Disease: A Clinical Update

Jeremy L. Herrmann, MDb, Aaron M. Abarbanell, MDb, Brent R. Weil, MDb, Yue Wang, PhDb, Meijing Wang, MDb, Jiangning Tan, MD, PhDb, Daniel R. Meldrum, MDa,b,c,d,*

a Clarian Cardiovascular Surgery, Indiana University School of Medicine, Indianapolis, Indiana
b Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana
c Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana
d Center for Immunobiology, Indiana University School of Medicine, Indianapolis, Indiana

* Address correspondence to Dr Meldrum, 635 Barnhill Dr, Van Nuys Medical Science Bldg, Room #2017, Indianapolis, IN 46202 (Email: dmeldrum{at}iupui.edu).

Progenitor cell therapy is a promising treatment for ischemic heart disease. Early clinical trials of autologous bone marrow-derived progenitor cell therapy for acute and chronic myocardial ischemia showed modest functional improvements after cell delivery; however, the duration of these benefits remains unclear. Ongoing investigations continue to enhance our understanding of the mechanisms by which progenitor and stem cells function and how their survival and cardioprotective abilities can be improved. This review discusses: (1) relevant progenitor and stem cells in myocardial regenerative therapy, (2) routes of cell delivery to ischemic myocardium, (3) clinical trials investigating bone marrow-derived progenitor cell therapy for myocardial ischemia, and (4) future directions of the field.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The Society of Thoracic Surgeons.